ResearcherMayo ClinicNo recent work listed

Matthew Rowley

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5102508041. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2011: 1 paper

Papers 1

Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Co-author DOI 10.1053/j.gastro.2010.12.039 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Thomas C. Smyrk · 1 shared paper, 2011 · strength 0.02
- Paper Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. DOI 10.1053/j.gastro.2010.12.039 ↗
Michael H. Muders · 1 shared paper, 2011 · strength 0.02
- Paper Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. DOI 10.1053/j.gastro.2010.12.039 ↗
Lin Yang · 1 shared paper, 2011 · strength 0.02
- Paper Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. DOI 10.1053/j.gastro.2010.12.039 ↗
Fergus Joseph Couch · 1 shared paper, 2011 · strength 0.02
- Paper Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. DOI 10.1053/j.gastro.2010.12.039 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.